Remove Clinical Research Remove Contract Manufacturing Remove Development
article thumbnail

Baxter to sell BPS business to Advent and Warburg Pincus for $4.25bn

Pharmaceutical Technology

BPS offers parenteral delivery systems, sterile contract manufacturing solutions and customised support services to the pharma and biotech industries. It will become an independent, end-to-end contract development and manufacturing organisation, as a separate company and in collaboration with Warburg Pincus and Advent International.

article thumbnail

Biopharmaceutical Contract Manufacturing: Transforming Promise into Reality

Roots Analysis

Over the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs. As a result, biopharmaceutical contract manufacturing has picked up pace in the recent years. The same is true for the biopharmaceutical contract services market.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biopharmaceutical Contract Manufacturing: Transforming Promise into Reality

Roots Analysis

Over the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs. As a result, biopharmaceutical contract manufacturing has picked up pace in the recent years. The same is true for the biopharmaceutical contract services market.

article thumbnail

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval

Pharmaceutical Technology

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

article thumbnail

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Cervical Intraepithelial Neoplasia (CIN): Likelihood of Approval

Pharmaceutical Technology

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

article thumbnail

Leading clinical packaging companies in contract marketing

Pharmaceutical Technology

Unlike commercial pharmaceutical packaging, the primary consideration in clinical trial packaging is protecting the product quality and reliability for research. Finding the best clinical trial packaging services providers.

Packaging 100
article thumbnail

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

XTalks

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This venture also led me to identify a gap in the market for contract manufacturing of recombinant proteins.